AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’

On CNBC’s “ Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked AstraZeneca PLC (NYSE: AZN ), Last week, Cambridge, U.K.-based AstraZeneca secured regulatory approval for a new breast cancer treatment while reporting strong Phase 3 trial data for its lung cancer and respiratory therapies. In August, the Financial Times reported that Bristol Myers Squibb (NYSE: BMY ) and AstraZeneca were considering a nearly $400 million merger. Don’t forget to check out our premarket coverage here. Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, named Leidos Holdings, Inc. (NYSE: LDOS ) as his final trade. Supporting his choice, Leidos reported better-than-expected second-quarter financial results on Aug. 4 and raised its FY26 guidance. Leidos reported quarterly earnings of $3.26 per share, which beat the analyst consensus estimate of $2.91 per share. The company reported quarterly sales of $4.558 billion, which beat the analyst consensus estimate of $4.437 billion. Liz Thomas, SoFi head of investment strategy, recommended US 10-year Treasury. Joseph M. Terranova, senior managing director for Virt